Citizens Jmp Cuts Athira Pharma (NASDAQ:LONA) Price Target to $17.00

Athira Pharma (NASDAQ:LONA) had its price objective cut by Citizens Jmp from $18.00 to $17.00 in a research report released on Monday,Benzinga reports. They currently have a market outperform rating on the stock.

Several other equities analysts have also commented on the company. Piper Sandler initiated coverage on Athira Pharma in a research report on Wednesday, May 27th. They set an “overweight” rating and a $20.00 price objective on the stock. Wall Street Zen upgraded shares of Athira Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Athira Pharma in a research note on Friday, August 7th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.33.

Athira Pharma Stock Down 4.2%

NASDAQ LONA opened at $7.83 on Monday. The company has a market cap of $73.52 million, a PE ratio of -1.86 and a beta of 2.04. Athira Pharma has a 52 week low of $3.52 and a 52 week high of $14.21. The firm’s 50-day simple moving average is $8.24 and its two-hundred day simple moving average is $8.31.

Athira Pharma (NASDAQ:LONA) last posted its earnings results on Friday, August 14th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.20). As a group, equities research analysts anticipate that Athira Pharma will post -2.76 EPS for the current year.

Institutional Trading of Athira Pharma

Institutional investors have recently made changes to their positions in the stock. Focus Partners Wealth bought a new position in shares of Athira Pharma in the third quarter worth approximately $35,000. Jane Street Group LLC bought a new stake in Athira Pharma during the 4th quarter valued at $100,000. Renaissance Technologies LLC raised its holdings in Athira Pharma by 44.7% during the 4th quarter. Renaissance Technologies LLC now owns 75,147 shares of the company’s stock valued at $569,000 after buying an additional 23,223 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in Athira Pharma during the 4th quarter valued at $969,000. Finally, Millennium Management LLC purchased a new stake in Athira Pharma during the 4th quarter valued at $2,456,000. Hedge funds and other institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system.